Biotech News
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantationRefined priming-dose regimen significantly reduces
